These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 9241361)
1. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. Rucińska M; Furman M; Skrzydlewski Z; Zaremba E Acta Biochim Pol; 1997; 44(1):109-12. PubMed ID: 9241361 [TBL] [Abstract][Full Text] [Related]
2. [Cancer procoagulant activity in cases of esophageal, stomach and colorectal cancer considering progression degree and histological type of cancer]. Kozuszko B; Skrzydlewski Z; Sulkowska M; Snarska J; Kozłowski M; Skrzydlewska E; Zalewski B Pol Merkur Lekarski; 2001 Sep; 11(63):218-20. PubMed ID: 11761814 [TBL] [Abstract][Full Text] [Related]
3. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Gordon SG; Cross BA Cancer Res; 1990 Oct; 50(19):6229-34. PubMed ID: 2169340 [TBL] [Abstract][Full Text] [Related]
4. [Diagnostic significance of cancer procoagulant activity in colorectal cancer]. Kozuszko B; Skrzydlewski Z; Famulski W Pol Merkur Lekarski; 2000 Mar; 8(45):127-8. PubMed ID: 10870414 [TBL] [Abstract][Full Text] [Related]
5. [Assessment of the efficacy of cancer procoagulant (CP) activity evaluation in the oncological diagnosis of the urinary system]. Szajda SD; Darewicz B; Kudelski J; Werel T; Zwierz K; Skrzydlewski Z; Gabrylewski W Pol Merkur Lekarski; 2005 Oct; 19(112):596-9. PubMed ID: 16379335 [TBL] [Abstract][Full Text] [Related]
6. [Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer]. Szajda SD; Darewicz B; Kudelski J; Chlabicz M; Domel T; Chabielska E; Skrzydlewski Z Pol Merkur Lekarski; 2005 Jun; 18(108):651-3. PubMed ID: 16124376 [TBL] [Abstract][Full Text] [Related]
7. Cancer procoagulant (CP) in lung cancer. Rucińska M; Skrzydlewski Z; Zaremba E; Furman M; Kasacka I Rocz Akad Med Bialymst; 1997; 42 Suppl 1():251-3. PubMed ID: 9337542 [TBL] [Abstract][Full Text] [Related]
8. [Hepatocyte growth factor in the sera of patients with gastrointestinal and breast cancer]. Narita T; Toi M; Sekiguchi K; Iwanari H; Matsuura N; Kimura N; Mitsuoka C; Kannagi R Gan To Kagaku Ryoho; 1997 Nov; 24(14):2159-62. PubMed ID: 9388530 [No Abstract] [Full Text] [Related]
9. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. Karapanagiotou EM; Pelekanou E; Charpidou A; Tsaganos T; Anagnostou V; Plachouras D; Giamarellos-Bourboulis EJ; Syrigos KN Anticancer Res; 2008; 28(2B):1411-5. PubMed ID: 18505088 [TBL] [Abstract][Full Text] [Related]
10. [Usefulness of detecting cancer procoagulant activity and thyrotropic hormone concentration in the differentiation of tumor-like changes in the thyroid]. Snarska J; Szajda SD; Knaś M; Mroczko B; Borzym-Kluczyk M; Kamiński F; Zwierz P; Zwierz K Wiad Lek; 2006; 59(5-6):332-5. PubMed ID: 17017477 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of examination of some tumor markers in diagnostics of liver cancer. Snarska J; Szajda SD; Puchalski Z; Szmitkowski M; Chabielska E; Kaminski F; Zwierz P; Zwierz K Hepatogastroenterology; 2006; 53(68):271-4. PubMed ID: 16608038 [TBL] [Abstract][Full Text] [Related]
12. Procoagulant activity in whole blood from patients with breast and colorectal cancer. Parmar J; Taylor I; Roath S; Francis J Blood Coagul Fibrinolysis; 1990 Jun; 1(2):127-32. PubMed ID: 2130924 [TBL] [Abstract][Full Text] [Related]
13. Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer. Kozuszko B; Skrzydlewska E; Snarska J; Kozłowski M; Zalewski B; Skrzydlewski Z Folia Histochem Cytobiol; 2001; 39 Suppl 2():104-5. PubMed ID: 11820560 [TBL] [Abstract][Full Text] [Related]
14. [Serum activity of chitotriosidase, lysozyme and cathepsin H in patients with lung cancer and patients with inflammatory exudate (preliminary report)]. Gołab K; Passowicz-Muszyńska E; Jankowska R; Warwas M Pol Merkur Lekarski; 2009 Mar; 26(153):194-7. PubMed ID: 19388531 [TBL] [Abstract][Full Text] [Related]
16. Assessment of coagulation disorders and cancer procoagulant activity in patients with myelodysplastic syndromes. Chojnowski K; Treliński J; Wawrzyniak E; Sobolewska M; Mielicki W Neoplasma; 2002; 49(3):155-8. PubMed ID: 12098000 [TBL] [Abstract][Full Text] [Related]
17. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752 [TBL] [Abstract][Full Text] [Related]
18. Vitamin D in colorectal, breast, prostate and lung cancer: a pilot study. Pazdiora P; Svobodova S; Fuchsova R; Kucera R; Prazakova M; Vrzalova J; Narsanska A; Strakova M; Treskova I; Pecen L; Treska V; Holubec L; Pesek M; Finek J; Topolcan O Anticancer Res; 2011 Oct; 31(10):3619-21. PubMed ID: 21965787 [TBL] [Abstract][Full Text] [Related]
19. New immunocapture enzyme (ICE) assay for quantification of cancer procoagulant activity: studies of inhibitors. Mielicki WP; Tagawa M; Gordon SG Thromb Haemost; 1994 Apr; 71(4):456-60. PubMed ID: 8052963 [TBL] [Abstract][Full Text] [Related]
20. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Rohayem J; Diestelkoetter P; Weigle B; Oehmichen A; Schmitz M; Mehlhorn J; Conrad K; Rieber EP Cancer Res; 2000 Apr; 60(7):1815-7. PubMed ID: 10766164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]